Abstract
Introduction: Synovial sarcoma (SS) is a malignant mesenchymal tumor. It is most common among children
and adults. The data on SS from India are scarce. In this study, we analyzed the clinicopathological
treatment parameters and survival outcomes of SS patients. Materials and Methods: A total of 57 histologically proven SS diagnosed from 2010 to 2016 were retrospectively
analyzed. Results: The median age was 23 years with a male-to-female ratio of 1.28:1. Localized disease
was seen in 44 patients (77%) and 13 patients (23%) had metastasis. The primary sites
of involvement such as lower limb, upper limb, thorax, and abdomen were seen in 60%,
28%, 7%, and 5% patients, respectively. Surgery was done in 39 patients and 18 patients
had unresectable disease. Adjuvant chemotherapy with doxorubicin-based regimen was
given in 30 patients and adjuvant radiotherapy in 21 patients. Palliative chemotherapy
with anthracycline-based or gemcitabine-based regimen was used in 17 and 2 patients,
respectively. The median event-free survival (EFS) was 30 months with 3 years and
EFS rate was 36%; median progression-free survival (PFS) was 11.5 months and 1 year;
and PFS rate was 38%. On univariate analysis, resection and performance status were
significantly associated with survival. There is no impact of grade and size of the
tumor on survival. In metastatic patients, the lung is the most common site. Conclusion: SS is the most common soft-tissue sarcoma among adults. Resectability and performance
status were impacting the survival.
Key words
Clinicopathological - survival - synovial sarcoma - treatment
